Abiopharma

(99% Neutral) PLIANT THERAPEUTICS, INC. (PLRX) Announces Business Combination

(99% Neutral) Illumina, Inc. (ILMN) Announces Business Combination

(82% Positive) EyePoint Pharmaceuticals, Inc. (EYPT) Provides Update on passion for her career

(85% Positive) Global Blood Therapeutics, Inc. (GBT) Announces Enrollment Update for authorized Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(99% Neutral) TherapeuticsMD, Inc. (TXMD) Announces Business Combination

(10% Negative) Ultragenyx Pharmaceutical Inc. (RARE) Announces Business Combination

(99% Neutral) Vir Biotechnology, Inc. (VIR) Announces Executive Changes

(99% Neutral) RUBIUS THERAPEUTICS, INC. (RUBY) Announces Clinical Development Update

(10% Negative) PACIRA BIOSCIENCES, INC. (PCRX) Announces Delay in sales Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Marinus Pharmaceuticals, Inc. (MRNS) Announces Delay in voucher Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process